NGM Biopharmaceuticals, Inc. Common Stock
NGM
NGM was delisted on the 4th of April, 2024.
114 hedge funds and large institutions have $730M invested in NGM Biopharmaceuticals, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 38 increasing their positions, 40 reducing their positions, and 20 closing their positions.
5% less repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 40
4% less funds holding
Funds holding: 119 → 114 (-5)
12% less capital invested
Capital invested by funds: $833M → $730M (-$103M)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
25% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CG
Column Group
San Francisco,
California
|
+$13.3M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$8.44M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$7.35M |
| 4 |
Morgan Stanley
New York
|
+$4.47M |
| 5 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$3.83M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$10.3M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$8.41M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$8.37M |
| 4 |
Millennium Management
New York
|
-$1.82M |
| 5 |
Two Sigma Investments
New York
|
-$1.4M |
NGM Hedge Fund Activity: Q1 2022 in Review
114 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in NGM Biopharmaceuticals, Inc. Common Stock (NGM) for Q1 2022, worth a combined $730M — down 12% from $833M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of NGM and 15 opened new positions — a net loss of 5 holders — while 40 trimmed existing stakes and 38 added.
The largest buyer was Column Group, adding an estimated $13.3M. The largest seller was Redmile Group, exiting entirely with an estimated $10.3M sold.
- 114 institutional investors held NGM Biopharmaceuticals, Inc. Common Stock (NGM) as of Q1 2022, down from 119 in Q4 2021.
- Funds reported $730M of NGM Biopharmaceuticals, Inc. Common Stock stock for Q1 2022, down 12% quarter-over-quarter.
- 15 funds opened new NGM Biopharmaceuticals, Inc. Common Stock positions in Q1 2022 and 20 closed out, a net change of -5 holders.
- The largest NGM Biopharmaceuticals, Inc. Common Stock buyer in Q1 2022 was Column Group, an estimated $13.3M added.
- The largest NGM Biopharmaceuticals, Inc. Common Stock seller in Q1 2022 was Redmile Group, an estimated $10.3M sold.
Based on aggregated 13F filings for Q1 2022.